eNeurologicalSci最新文献_第5页

Is there a link between Hepatitis A virus and Guillain-Barré syndrome? A systematic review of case reports a型肝炎病毒与格林-巴-罗综合征之间是否存在联系？对病例报告进行系统审查。

eNeurologicalSci Pub Date : 2025-03-01 Epub Date: 2025-01-06 DOI: 10.1016/j.ensci.2025.100551

Amirhosein Ghasemi , Nima Broomand Lomer , Alia Saberi

{"title":"Is there a link between Hepatitis A virus and Guillain-Barré syndrome? A systematic review of case reports","authors":"Amirhosein Ghasemi , Nima Broomand Lomer , Alia Saberi","doi":"10.1016/j.ensci.2025.100551","DOIUrl":"10.1016/j.ensci.2025.100551","url":null,"abstract":"<div><h3>Introduction</h3><div>Guillain-Barré syndrome (GBS) is an inflammatory disorder of the peripheral nervous system, causing acute flaccid paralysis. There have been occasional reports linking Hepatitis A virus (HAV) to GBS. Here we aimed to evaluate the current literature on the association between GBS and HAV, exploring potential mechanisms and clinical implications.</div></div><div><h3>Methods</h3><div>We conducted a systematic search using PRISMA guidelines in PubMed, Web of Science, Embase, and Scopus. Only published case reports or conference abstracts presenting cases of confirmed HAV infection and GBS were included. Data extraction was performed independently by two reviewers, and quality assessment was conducted using the Joanna Briggs Institute critical appraisal tool.</div></div><div><h3>Results</h3><div>Out of 581 studies identified, 46 studies encompassing 47 cases met the inclusion criteria. The mean age of patients was 29.47 years, with a male predominance (70.2 %). Geographically, most cases were reported in Asia (74.5 %). Clinical manifestations of HAV included fever, malaise, and jaundice, while GBS presented with muscle weakness and areflexia. Laboratory findings showed albuminocytological dissociation in 76.2 % of cases. Nerve conduction studies predominantly indicated AIDP subtype (32/46, 69.6 %). Treatment involved IVIG, plasmapheresis, and supportive care, with recovery times ranging from one week to 18 months. One fatality was reported.</div></div><div><h3>Conclusions</h3><div>This review suggests a potential link between HAV infection and GBS, proposing a mechanism: molecular mimicry. It emphasizes the need for increased awareness and preventive measures, especially in areas with lower health standards. However, further research is needed to clarify the possible mechanisms and deepen our understanding.</div></div>","PeriodicalId":37974,"journal":{"name":"eNeurologicalSci","volume":"38 ","pages":"Article 100551"},"PeriodicalIF":0.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11763178/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143047858","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Impact of COVID-19 on functional, cognitive, neuropsychiatric, and health-related outcomes in patients with dementia: A systematic review COVID-19对痴呆患者功能、认知、神经精神和健康相关结局的影响：一项系统综述

eNeurologicalSci Pub Date : 2025-03-01 Epub Date: 2024-11-21 DOI: 10.1016/j.ensci.2024.100539

Lucia Crivelli , Andrea Winkler , Greta Keller , Simone Beretta , Ismael Luis Calandri , Wouter De Groote , Arianna Fornari , Jennifer Frontera , Miia Kivipelto , Ana Sabsil Lopez-Rocha , Francesca Mangialasche , Daniel Munblit , Katie Palmer , Alla Guekht , Ricardo Allegri

{"title":"Impact of COVID-19 on functional, cognitive, neuropsychiatric, and health-related outcomes in patients with dementia: A systematic review","authors":"Lucia Crivelli , Andrea Winkler , Greta Keller , Simone Beretta , Ismael Luis Calandri , Wouter De Groote , Arianna Fornari , Jennifer Frontera , Miia Kivipelto , Ana Sabsil Lopez-Rocha , Francesca Mangialasche , Daniel Munblit , Katie Palmer , Alla Guekht , Ricardo Allegri","doi":"10.1016/j.ensci.2024.100539","DOIUrl":"10.1016/j.ensci.2024.100539","url":null,"abstract":"<div><h3>Background</h3><div>This systematic review analyzes the impact of COVID-19 on dementia patients' functional, cognitive, neuropsychiatric, and health related outcomes. It hypothesizes that dementia patients infected with SARS-CoV-2experience more pronounced deterioration compared to those who are uninfected.</div></div><div><h3>Methods</h3><div>Research from 01/03/2020 to 07/10/2023 was conducted using Medline, Web of Science, and Embase databases, and adhering to PRISMA guidelines and the PICO framework. The study aimed to determine if SARS-CoV-2 infection is associated with worse outcomes in dementia patients. The protocol is registered in PROSPERO (CRD42022352481), and bias was evaluated using the Newcastle-Ottawa Scale.</div></div><div><h3>Results</h3><div>Among 198 studies reviewed, only three met the criteria. Chen et al. (2023) identified higher mortality in SARS-CoV-2-infected dementia patients, while Merla et al. (2023) observed faster cognitive decline in infected individuals with increased hospital admissions. Additionally, Cascini et al. (2022) reported an increased risk of infection and significantly elevated mortality in dementia patients, highlighting comorbidities and antipsychotic medication use as key risk factors.</div></div><div><h3>Conclusion</h3><div>These limited data suggest higher mortality and cognitive decline in dementia patients following COVID-19, underscoring the need for extensive research in this area.</div></div>","PeriodicalId":37974,"journal":{"name":"eNeurologicalSci","volume":"38 ","pages":"Article 100539"},"PeriodicalIF":0.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11663964/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142886230","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Neuroepidemiology: Basic concepts and population surveys 神经流行病学：基本概念和人口调查。

eNeurologicalSci Pub Date : 2025-03-01 Epub Date: 2024-12-03 DOI: 10.1016/j.ensci.2024.100544

Walter A. Rocca

引用次数: 0

Neuropathy and the metabolic syndrome 神经病变和代谢综合征。

eNeurologicalSci Pub Date : 2025-03-01 Epub Date: 2024-11-28 DOI: 10.1016/j.ensci.2024.100542

Nicoló Piccolo , Astrid Wiggers , Emily J. Koubek, Eva L. Feldman

引用次数: 0

Randomized clinical trial (RCT): An overview 随机临床试验：综述。

eNeurologicalSci Pub Date : 2025-03-01 Epub Date: 2025-01-02 DOI: 10.1016/j.ensci.2025.100547

Giancarlo Logroscino

引用次数: 0

Deterioration of preexisting myoclonus following nifedipine use in parkinsonian syndrome: A case report 硝苯地平治疗帕金森综合征后原有肌阵挛恶化1例报告。

eNeurologicalSci Pub Date : 2025-03-01 Epub Date: 2024-12-15 DOI: 10.1016/j.ensci.2024.100545

Gohei Yamada , Takanari Toyoda , Eiichi Katada , Noriyuki Matsukawa

{"title":"Deterioration of preexisting myoclonus following nifedipine use in parkinsonian syndrome: A case report","authors":"Gohei Yamada , Takanari Toyoda , Eiichi Katada , Noriyuki Matsukawa","doi":"10.1016/j.ensci.2024.100545","DOIUrl":"10.1016/j.ensci.2024.100545","url":null,"abstract":"<div><div>L-type calcium channel antagonists are uncommon causes of myoclonus, and the underlying mechanism remains unclear. Here, we report a case of parkinsonian syndrome with deterioration of preexisting myoclonus after nifedipine use. A 96-year-old woman was administered a single dose of sustained-release nifedipine for chest pain. One hour later, the patient developed shock-like jerky movements in the trunk and upper and lower limbs. Neurological examination revealed myoclonus, intention tremor in both hands, facial hypomimia, stooped posture, short stride length, absent arm swing during walking, and muscle rigidity in the neck, left arm, and both legs. Brain magnetic resonance imaging showed no causative lesions, suggesting a nifedipine-induced movement disorder. Myoclonic movements almost completely resolved within 24 h. Despite no further administration of nifedipine, a neurological examination one week later revealed parkinsonism with mild myoclonus and intention tremor. It appeared that preexisting myoclonus and intention tremor transiently worsened with nifedipine use. The patient was diagnosed with parkinsonian syndrome with deterioration of myoclonus due to nifedipine administration. This case suggests that the corticostriatal pathways may have already been impaired and were further affected by nifedipine. Nifedipine-induced alterations in dopaminergic and serotonergic systems may have contributed to the deterioration of myoclonus and intention tremor. When patients present with myoclonus after taking an L-type calcium channel antagonist, underlying neurological disorders should be carefully investigated.</div></div>","PeriodicalId":37974,"journal":{"name":"eNeurologicalSci","volume":"38 ","pages":"Article 100545"},"PeriodicalIF":0.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11732187/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142984908","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Update in multiple sclerosis 多发性硬化症最新进展。

eNeurologicalSci Pub Date : 2025-03-01 Epub Date: 2025-01-11 DOI: 10.1016/j.ensci.2025.100553

Bassem Yamout

引用次数: 0

Recognizing familial Huntington's disease in an Asian cohort: Insights from the Philippines 在亚洲队列中识别家族性亨廷顿舞蹈病：来自菲律宾的见解

eNeurologicalSci Pub Date : 2025-03-01 Epub Date: 2025-01-26 DOI: 10.1016/j.ensci.2025.100558

Jao Jarro B. Garcia , Gilbert J. Cabataña Jr , Iris Ditan , Karl Josef Niño J. Separa , Ida Ingrid Rocha-Tulagan , Han-I Lin , Chin-Hsien Lin , Melanie Leigh D. Supnet-Wells , Alejandro F. Diaz , Arlene R. Ng , Roland Dominic G. Jamora , Gerard Saranza

{"title":"Recognizing familial Huntington's disease in an Asian cohort: Insights from the Philippines","authors":"Jao Jarro B. Garcia , Gilbert J. Cabataña Jr , Iris Ditan , Karl Josef Niño J. Separa , Ida Ingrid Rocha-Tulagan , Han-I Lin , Chin-Hsien Lin , Melanie Leigh D. Supnet-Wells , Alejandro F. Diaz , Arlene R. Ng , Roland Dominic G. Jamora , Gerard Saranza","doi":"10.1016/j.ensci.2025.100558","DOIUrl":"10.1016/j.ensci.2025.100558","url":null,"abstract":"<div><div>Huntington's Disease (HD) is an autosomal-dominant, neurodegenerative condition characterized by extrapyramidal, psychiatric, and cognitive disturbances. In the Philippines, only one genetically confirmed sporadic case had been previously reported. This study aims to present ten additional cases of genetically proven familial HD. All cases were of pure Filipino descent, aged 27–65. Six were males, and nine had at least one relative who manifested with the same symptomatology. The youngest age at onset was 21 years old. Nine initially manifested with chorea, whereas one manifested initially with behavioral change. At the time of consult, eight already had cognitive changes exemplified by memory lapses, while six also manifested behavioral or psychiatric disturbances. Workup revealed caudate atrophy in six and cerebral atrophy in five of the cases. All tested positive on genetic testing with the CAG trinucleotide spanning 41 to 53 repeats. The clinical profile of our patients did not differ from the known and published natural course of HD. To date, HD remains underrecognized in the Philippines. Although rare in Asian countries, it should still be a differential for a patient with chorea, cognitive decline, behavioral changes, and a strong family history of the same symptomatology.</div></div>","PeriodicalId":37974,"journal":{"name":"eNeurologicalSci","volume":"38 ","pages":"Article 100558"},"PeriodicalIF":0.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143146059","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Oral minocycline therapy as first-line treatment in patients with Myalgic encephalomyelitis and long COVID: A pilot study 口服二甲胺四环素作为肌痛性脑脊髓炎和长COVID患者的一线治疗：一项初步研究。

eNeurologicalSci Pub Date : 2025-03-01 Epub Date: 2024-12-02 DOI: 10.1016/j.ensci.2024.100537

Kunihisa Miwa

{"title":"Oral minocycline therapy as first-line treatment in patients with Myalgic encephalomyelitis and long COVID: A pilot study","authors":"Kunihisa Miwa","doi":"10.1016/j.ensci.2024.100537","DOIUrl":"10.1016/j.ensci.2024.100537","url":null,"abstract":"<div><h3>Background</h3><div>Myalgic encephalomyelitis (ME) is associated with long COVID and also untoward sequelae after anti-coronavirus vaccination. Recently, oral minocycline therapy has been reported to ameliorate symptoms in patients with ME, particularly at the initial stage of the disease.</div></div><div><h3>Methods</h3><div>Oral minocycline (100 mg × 2 on the first day, followed by 100 mg/day for 41 days) was administered to 55 patients with ME that emerged during the “Corona era,” including 19 patients with long COVID and 5 patients diagnosed with untoward sequalae following coronavirus vaccination.</div></div><div><h3>Results</h3><div>Acute adverse effects including nausea and/or dizziness caused four (7 %) patients to discontinue treatment in the first few days. Among the other 51 patients who completed therapy, favorable effects were observed, including a decrease in performance status score or index for restricted activities of daily living ≥2 points in 41 (80 %) patients. Disease duration was inversely associated with the favorable therapeutic effects (<em>p</em> = 0.02) and the disease duration within 6 months was significantly associated with the favorable therapeutic effects (27/30, 90 %, <em>p</em> = 0.02, hazard ratio: 3.6, 95 % confidence interval, 1.2<strong>–</strong>10.6). The favorable effects were observed in 16 (89 %) of 18 patients with long COVID. Significant amelioration of subjective symptoms of fatigue, post-exertional malaise, unrefreshing sleep, brain fog, disequilibrium, orthostatic intolerance, and neuropathic pain were observed.</div></div><div><h3>Conclusions</h3><div>Oral minocycline was effective at ameliorating symptoms in patients with ME including long COVID and post-coronavirus vaccination sequalae. It represents an effective first-line therapeutic option for these patients in the initial stage.</div></div>","PeriodicalId":37974,"journal":{"name":"eNeurologicalSci","volume":"38 ","pages":"Article 100537"},"PeriodicalIF":0.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11665601/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142886236","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Corrigendum to “Oral minocycline therapy as first-line treatment in patients with Myalgic encephalomyelitis and long COVID: A pilot study” [eNeurologicalSci 38 (2025) 100537]. “口服二甲胺四环素作为肌痛性脑脊髓炎和长COVID患者的一线治疗：一项试点研究”[enneurologicalsci 38(2025) 100537]。

eNeurologicalSci Pub Date : 2025-03-01 Epub Date: 2025-01-24 DOI: 10.1016/j.ensci.2025.100557

Kunihisa Miwa

引用次数: 0